Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

Research output: Contribution to journalArticle

Abstract

Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor, has shown activity in phase 2 trials in this setting. We investigated the combination of nintedanib with standard carboplatin and paclitaxel chemotherapy in patients with newly diagnosed advanced ovarian cancer.

Details

Authors
  • Andreas du Bois
  • Gunnar Kristensen
  • Isabelle Ray-Coquard
  • Alexander Reuss
  • Sandro Pignata
  • Nicoletta Colombo
  • Ursula Denison
  • Ignace Vergote
  • Jose M Del Campo
  • Petronella Ottevanger
  • Martin Heubner
  • Thomas Minarik
  • Emmanuel Sevin
  • Nikolaus de Gregorio
  • Mariusz Bidziński
  • Jacobus Pfisterer
  • Susanne Malander
  • Felix Hilpert
  • Mansoor R Mirza
  • Giovanni Scambia
  • And 7 others
  • Werner Meier
  • Maria O Nicoletto
  • Line Bjørge
  • Alain Lortholary
  • Martin Oliver Sailer
  • Michael Merger
  • Philipp Harter
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Pages (from-to)78-89
JournalThe Lancet Oncology
Volume17
Issue number1
Publication statusPublished - 2016
Publication categoryResearch
Peer-reviewedYes